KITE 222
Alternative Names: KITE-222Latest Information Update: 22 Jun 2024
At a glance
- Originator Kite Pharma
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 25 Apr 2024 Discontinued - Phase-I for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA, France (IV) due to futility (NCT04789408)
- 27 Oct 2022 KITE 222 receives Orphan Drug status for Acute myeloid leukaemia (Second-line therapy or greater) in USA
- 01 Jun 2021 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV) (NCT04789408)